Abstract
Toxic metabolites (N-acetylisoniazid, pyrazinoic acid, and desacetylrifampicin) of first-line anti-tuberculosis drugs (ethambutol, pyrazinamide, rifampicin, and isoniazid) are identified by liquid chromatography–mass spectrometry, which is important in selecting the required dosages of these drugs for the maximum therapeutic effects and the reduction of side effects. Characteristic chromatographic profiles of blood plasma samples from donors with pulmonary tuberculosis (“pathology”) and a clinically healthy group (“norm”) are obtained and processed by principal component analysis and the k-nearest neighbor method. A perspective of this approach for obtaining of additional diagnostic criteria for pulmonary tuberculosis is shown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
